Title: Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes
Abstract: Diabetes, Obesity and MetabolismVolume 13, Issue 3 p. 207-220 Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes M. J. Davies, Corresponding Author M. J. Davies Department of Cardiovascular Sciences, University of Leicester, Leicester, UKProf. Melanie J. Davies, Department of Cardiovascular Sciences, University of Leicester, Infirmary Square, Leicester LE1 5WW, UK.E-mail: [email protected]Search for more papers by this authorR. Kela, R. Kela University Hospitals of Leicester NHS Trust, Leicester, UKSearch for more papers by this authorK. Khunti, K. Khunti Department of Health Sciences, University of Leicester, Leicester, UKSearch for more papers by this author M. J. Davies, Corresponding Author M. J. Davies Department of Cardiovascular Sciences, University of Leicester, Leicester, UKProf. Melanie J. Davies, Department of Cardiovascular Sciences, University of Leicester, Infirmary Square, Leicester LE1 5WW, UK.E-mail: [email protected]Search for more papers by this authorR. Kela, R. Kela University Hospitals of Leicester NHS Trust, Leicester, UKSearch for more papers by this authorK. Khunti, K. Khunti Department of Health Sciences, University of Leicester, Leicester, UKSearch for more papers by this author First published: 18 November 2010 https://doi.org/10.1111/j.1463-1326.2010.01330.xCitations: 56Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Type 2 diabetes is characterized by a progressive decline in glycaemic control. Many standard diabetes treatments, however, fail to achieve or maintain glycaemic control, and are often associated with an increased risk of hypoglycaemia and weight gain. Recently developed incretin-based therapies are a promising addition to the current armamentarium of diabetes treatments. Two types of incretin-based therapies are currently available: glucagon-like peptide (GLP)-1 receptor agonists (liraglutide and exenatide) and dipeptidyl peptidase-4 inhibitors (sitaglipin, vildagliptin and saxagliptin). This review aims to summarize the key efficacy and safety data of liraglutide, a once-daily human GLP-1 analogue. Extensive phase III clinical trials have shown liraglutide to improve glycaemic control with additional benefits on body weight, blood pressure and β-cell function. Liraglutide is also generally well tolerated with a low risk of hypoglycaemia. Liraglutide has recently been approved for marketing in Europe, Japan and the USA. References 1 Nathan DM, Buse JB, Davidson MB et al., for the American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustments of therapy: a consensus statement of the American Diabetes Association and the European Association for Study of Diabetes. Diabetes Care 2009; 32: 193–203. 2 Wajchenberg BL. β-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187–218. 3 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865 (published correction appears in Lancet 1998; 352: 1558). 4 Kahn SE, Haffner SM, Heise MA et al., for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427–2443 (published correction appears in N Engl J Med 2007; 29: 356). 5 Davis TM, Cull CA, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55). Diabetes Care 2001; 24: 1167–1174. 6 Stratton IM, Adler AL, Neil HAW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–412. 7 McFarlane SI, Jacober SJ, Winer N et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centres. Diabetes Care 2006; 25: 718–723. 8 Fox KM, Gerber RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006; 28: 388–395. 9 Gerstein HC, Miller ME, Byington RP et al., for the Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med 2008; 358: 2545–2559. 10 Riddle MC, Rosenstock J, Gerich J, for the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine of human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080–3086. 11 Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006; 49: 253–260. 12 Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929–2940. 13 Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131–2157. 14 Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409–1439. 15 Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824–830. 16 Vilsbøll T, Agersø H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88: 220–224. 17 Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46–52. 18 Holst JJ, La Salle JR. An overview of incretin hormones. J Family Pract 2008; 57(Suppl): S4–9. 19 Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675–688. 20 Ristic S, Byiers S, Foley J, Holems D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005; 7: 692–698. 21 Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696–1705. 22 DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycaemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092–1100. 23 Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195–202. 24 Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type 2 diabetic patients. Diabetologia 2002; 45: 1111–1119. 25 Rosenstock J, Gumprecht J, Szyprowska E et al. Pharmacokinetics of liraglutide vs exenatide in type 2 diabetes: sustained vs fluctuating concentrations over 24 hours. Diabetes 2009; 58(Suppl. 1): A150. 26 Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996; 31: 665–670. 27 Linnebjerg H, Kothare PA, Park S et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 317–327. 28 Helleberg H, Malm-Erjefalt M, Bjornsdottir I et al. Metabolism and excretion of [Pal-3H]-liraglutide in human healthy subjects. Diabetes 2008; 57(Suppl. 1): A581–A582. 29 Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharamcokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009; 68: 898–905. 30 Knudsen LB, Nielsen PF, Huusfeldt PO et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664–1669. 31 Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Diabetes 2008; 57(Suppl. 1): A164. 32 Elbrønd B, Jakobsen G, Larsen S et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25: 1398–1404. 33 Degn KB, Juhl CB, Sturis J et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187–1194. 34 Farilla L, Hui H, Bertolotto C et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetes rats. Endocrinology 2002; 143: 4397–4408. 35 Farilla L, Bulotta A, Hirshberg B et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149–5158. 36 Rolin B, Larsen MO, Gotfredsen CF et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745–E752. 37 Sturis J, Gotfredsen CF, Rømer J et al. GLP-1 derivative liraglutide in rats with β-cell deficiencies: influence of metabolic state on β-cell mass dynamics. Br J Pharmacol 2003; 140: 123–132. 38 Rutti S, Prozak R, Ellingsgaard H et al. Liraglutide induces human β-cell proliferation, counteracts low-density lipoprotein anti-proliferative effects and protects from IL-1β induced apoptosis. Diabetes 2009; 58(Suppl. 1): A410. 39 Ribel U, Larsen MO, Rolin B et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol 2002; 451: 217–225. 40 Larsen PJ, Fledelius C, Knudsan LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001; 50: 2530–2539. 41 Raun K, von Voss P, Knudsen LB. Liraglutide, a once-daily human glucagon-like peptide-1 analog, mininmizes food intake in severely obese minipigs. Obesity 2007; 15: 1710–1716. 42 Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007; 56: 8–15. 43 Noyan-Ashraf MH, Momen MA, Ban K et al. GLP-1R agonist liraglutide activates cytoprotective pathways improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58: 975–983. 44 Kristensen J, Mortensen UM, Schmidt M, Nielsen PH, Nielsen TT, Maeng M. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord 2009; 9: 31. 45 Knudsen LB, Madsen LW, Andersen S et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151: 1473–1486. 46 Costante G, Durante C, Francis Z, Schlumberger M, Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab 2009; 5: 35–44. 47 Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004; 61: 299–310. 48 Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR, for the NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care 2004; 27: 1335–1342. 49 Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004; 27: 1915–1921. 50 Vilsbøll T, Zdravkovi M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608–1610. 51 Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268–278. 52 Nauck MA, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009; 32; 84–90. 53 Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473–481. 54 Zinman B, Gerich J, Buse JB et al., (LEAD 4). Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224–1230. 55 Russell-Jones D, Vaag A, Schmitz O et al., (LEAD 5). Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046–2055. 56 Buse JB, Rosenstock J, Sesti G et al. A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomised, 26-week, open-label trial (LEAD-6). Lancet 2009; 374: 39–47. 57 Nauck MA, Vaag A, Colagiuri S et al. HbA1c reduction with liraglutide in type 2 diabetes patients is associated with initial HbA1c levels. International Diabetes Federation—20th World Diabetes Congress, 2009, P–1400. 58 Holst JJ, Nauck M, Brett J, Falahati A, Pratley R. Improvement in glycaemic control when adding liraglutide to existing therapy: results from a meta-analysis of six large randomised clinical trials. Diabetologia 2009; 52(Suppl 1): S288. 59 Schmidt WE, Gough S, Madsbad NS et al. Liraglutide, a human GLP-1 analogue, lowers HbA1c independent of weight loss. Diabetologia 2009; 52(Suppl 1): S289. 60 Garber A, Henry R, Ratner R, Hale P, Chang CT, Bode B. Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1C, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results. Diabetes 2009; 58(Suppl. 1): A42. 61 Schmitz O, Russell-Jones D, Shaw J et al. Liraglutide, a human GLP-1 analogue, reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline. Diabetologia 2008; 51(Suppl 1): S354. 62 Jendle J, Nauck MA, Matthews DR et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009; 11: 1163–1172. 63 Barzilai N, Gabriely I. The role of fat depletion in the biological benefits of caloric restriction. J Nutr 2001; 131: 903S–906S. 64 Lebovitz HE, Banerji MA. Point: visceral adiposity is causally related to insulin resistance. Diabetes Care 2005; 28: 2322–2325. 65 Matthews DR, Falahati A, Toft AD, Meier J. Liraglutide is associated with a significantly greater improvement in glycaemic control than glimepiride in patients with highest baseline β-cell function. Diabetologia 2009; 52(Suppl 1): S8. 66 Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association [published correction appears in Circulation 2000; 101: 1629–1631]. Circulation 1999; 100: 1134–1146. 67 Patel A, MacMahon S, Chalmers J et al., ADVANCE Collaborative group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–840. 68 Gallwitz B, Vaag A, Falahati A, Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract 2010; 64: 267–276. 69 Fonseca V, Madsbad S, Falahati A, Zychma MJ, Plutzky J. Once-daily human GLP-1 analog liraglutide reduces systolic blood pressure—a meta-analysis of 6 clinical trials. Diabetes 2009; 58(Suppl. 1): A146. 70 Plutzky J, Garber A, Toft AD, Poulter NR. Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in T2D. Diabetologia 2009; 52(Suppl 1): S299. 71 Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628–2635. 72 Liraglutide Summary of Product Characteristics. 2010. Available from URL: http://www.medicines.org.uk/EMC/medicine/21986/SPC/Victoza+6+mg+ml+solution+for+injection+in+pre-filled+pen/. Accessed April 2010. 73 Davidson J, Falahati A, Brett J. Mild renal impairment has no effect on the efficacy and safety of liraglutide (Abstract 235). AACE 2009. Available from URL: http://www.aace.com/meetings/ams/2009/pdf/ABSTRACTS.pdf. Accessed 22 September 2010. 74 Liraglutide US Prescribing Information. Available from URL: http://www.victoza.com/pdf/PI_(1_Column_Format).pdf. Accessed April 2010. 75 Noel RA, Braun DK, Pattarson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes. Diabetes Care 2009; 32: 834–838. 76 FDA. FDA briefing document. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM148659.pdf. Accessed May 2010. 77 Zinman B, Buse J, Falahati A, Moses A, Gough S. Liraglutide more effectively achieves a composite endpoint for A1C, SBP and weight change than other diabetes therapies. Diabetes 2009; 58(Suppl. 1): A143. 78 Zinman B, Buse J, Falahati S, Moses A. Attaining a clinically relevant endpoint of HbA1c <7.0%, no weight gain and no hypoglycaemia with liraglutide as compared to other therapies in type 2 diabetes mellitus: a meta-analysis of the LEAD studies. Diabetologia 2009; 52(Suppl 1): S291. 79 Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin in patients with type 2 diabetes inadequately controlled on metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447–1456. 80 Buse J, Sesti G, Schmidt WE et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010; 33: 1300–1303. 81 Buse J, Montanya E, Sesti G et al. Frequency and magnitude of antibody formation are lower with liraglutide than exenatide: LEAD-6 results. Diabetes 2010; 59(Suppl. 1): A184. Citing Literature Volume13, Issue3March 2011Pages 207-220 ReferencesRelatedInformation
Publication Year: 2011
Publication Date: 2011-01-24
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 66
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot